PATENT CLAIM ANALYSIS

Application Number: 15868272
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "006400"]

Abstract:
The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.

Claim (Index 56):
The article of manufacture of  claim 53  which is a re-usable pen injector.

Metadata:
- Claim Count in Document: 77.0
- Percentile: 86.0
- Lexical Diversity: 1.29412
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15241412', '14963279', '14781342', '15259101', '13507262']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7318145506571349
- 35 USC 102 Novelty (BERT): 0.5519952651884861
- Combined Prediction Score: 0.71383262211027
- Mean Citation Score: 340.59009
- Max Citation Score: 409.67368
- Similarity Product: 260.59650218998434

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test